| # | % | |||||
|---|---|---|---|---|---|---|
| 301 | QUIDEL CORP COM | 331,800 | 6,264,000 | 1.20% | ||
| 302 | Marcus & Millichap Inc Com | 138,189 | 6,355,000 | 1.22% | ||
| 303 | RETROPHIN INC | 313,695 | 6,355,000 | 1.22% | ||
| 304 | IMPRIVATA INC | 362,300 | 6,438,000 | 1.23% | ||
| 305 | NAUTILUS INC | 433,800 | 6,507,000 | 1.24% | ||
| 306 | Q2 Holdings Inc | 271,442 | 6,710,000 | 1.28% | ||
| 307 | CROSS CTRY HEALTHCARE INC COM | 498,000 | 6,778,000 | 1.30% | ||
| 308 | GTT COMMUNICATIONS INC COM | 334,262 | 7,775,000 | 1.49% | ||
| 309 | INTRA-CELLULAR THERAPIES INC | 205,657 | 8,235,000 | 1.58% | ||
| 310 | EAGLE PHARMACEUTICALS INC COM | 119,900 | 8,876,000 | 1.70% | ||
| 311 | Callidus Software Inc | 753,687 | 12,805,000 | 2.45% | ||
| 312 | 2U, Inc. | 387,210 | 13,901,000 | 2.66% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000828405-15-000006, filed 2015.11.12).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
